Speakers in Seoul said keeping patients on treatment is the next battleground, with ideas ranging from monthly shots to candidates that D&D says spare muscle.
Recap by typeshit. Full story at DongA Science.
Researchers compared short-term glycemic response to tirzepatide in type 2 diabetes patients based on whether they had used incretin drugs before.
Part of his GLP-1 series, Krittanawong discusses whether the drugs could help MASLD and MASH, and how visceral fat can drive metabolic problems unseen.
16:32
Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
Doctors report two patients who developed perianal abscesses while on tirzepatide. A case report, not proof the drug caused them.
Bone structure and formation rates didn't change, and the authors say the signal isn't enough to show a lasting bone-building effect.
Loading…